AN2 Therapeutics (ANTX) Invested Capital (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Invested Capital data on file, last reported at $81.8 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $81.8 million, up 11.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $81.8 million (up 11.5% YoY), and the FY2025 annual result was $53.1 million, down 35.17% from the prior year.
• Invested Capital advanced to $81.8 million in Q1 2026 per ANTX's latest filing, from $53.1 million in the prior quarter.
• Over five years, Invested Capital peaked at $139.0 million in Q3 2023 and troughed at $53.1 million in Q4 2025.
• A 5-year average of $93.1 million and a median of $87.8 million in 2023 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2024: Invested Capital surged 599.31% in 2022, then tumbled 36.91% in 2024.
• A 5-year view of Invested Capital shows it stood at $95.4 million in 2022, then soared by 30.75% to $124.7 million in 2023, then sank by 34.36% to $81.8 million in 2024, then plunged by 35.17% to $53.1 million in 2025, then jumped by 54.09% to $81.8 million in 2026.
• Business Quant data shows ANTX's Invested Capital at $81.8 million in Q1 2026, $53.1 million in Q4 2025, and $60.4 million in Q3 2025.